異位性皮膚炎市場：現況分析與預測（2023-2030）

Atopic Dermatitis Market: Current Analysis and Forecast (2023-2030)

出版日期: 2024年02月01日 | 出版商:

UnivDatos Market Insights Pvt Ltd | 英文 158 Pages | 商品交期: 最快1-2個工作天內

價格

簡介目錄

預計 2023 年至 2030 年異位性皮膚炎市場的複合年增長率約為 11.2%。異位性皮膚炎（AD），也稱為濕疹，是一種以發紅、搔癢和發炎為特徵的慢性發炎性皮膚病。它通常開始於嬰兒期或兒童期，但可能持續到成年期。 AD被認為是遺傳、免疫和環境因素綜合作用的結果，包括皮膚屏障缺陷、免疫系統失調以及接觸過敏原和刺激物。異位性皮膚炎是一種廣泛存在的慢性發炎性皮膚病，其盛行率在全球範圍內不斷增加，特別是在已開發國家，推動了異位性皮膚炎（AD）市場的發展。例如，根據世界過敏組織 (WAO) 的數據，兒童 AD 盛行率為 15% 至 30%，成人為 2% 至 10%。此外，全球醫療保健支出的增加使患者能夠更好地獲得醫療保健服務和異位性皮膚炎等慢性疾病的治療。例如，根據《JAMA Dermatology》發表的一項研究，2018 年美國異位性皮膚炎的年度費用超過 53 億美元，其中大部分費用來自處方藥和門診。

依藥物類別，市場分為皮質類固醇、PDE4 抑制劑、鈣調神經磷酸酶抑制劑、皮膚屏障潤膚劑等。其中，皮質類固醇已被證明可有效控制與 AD 相關的發炎和搔癢，且與一些新療法相比應用廣泛，且價格相對便宜，預計市場複合年增長率較高。皮質類固醇，無論是局部使用還是全身使用，長期以來一直是治療 AD 的主要藥物，有助於快速緩解症狀並限制病情發作。因此，它仍然是醫療保健提供者和患者中治療輕度至中度 AD 以及作為嚴重病例的輔助治療的熱門選擇。

根據最終用戶，市場分為醫院藥房、零售藥房和線上藥房。特別是，預計在預測期內，醫院藥局將越來越多地採用異位性皮膚炎藥。由於多種因素，包括異位性皮膚炎(AD) 盛行率的增加、新治療方案的出現以及醫院環境中對專業護理的需求不斷增長，醫院藥房部門見證了特應性皮膚炎(AD) 市場的增長。醫院在 AD 治療中發揮重要作用，特別是在需要重症監護、多學科護理和先進治療的嚴重病例中。製藥公司不斷開發和推出新的 AD 治療方法，包括生物製劑、小分子抑制劑和新型外用藥物。此外，醫院藥局可能會提供專門的複方藥物調配服務，以滿足 AD 患者的獨特需求。

為了更瞭解異位性皮膚炎產業的市場實施情況，市場包括北美（美國、加拿大、北美其他地區）、歐洲（德國、英國、法國、西班牙、義大利、歐洲其他地區）、亞太地區（中國、日本、印度、亞太地區其他地區）和世界其他地區。由於異位性濕疹盛行率不斷增加、一般人群對異位性皮膚炎的認識不斷增強以及生活方式的改變，北美異位性皮膚炎市場預計將繼續增長。例如，根據 eczema.org 的數據，到 2020 年，美國將有 3,160 萬人（10.1%）患有某種形式的濕疹，盛行率在兒童早期達到高峰。據估計，十分之一的人在一生中會患上濕疹，患病率在兒童早期達到高峰。

The Atopic Dermatitis market is expected to register a CAGR of approx. 11.2% over the period of 2023-2030. Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin condition characterized by red, itchy, and inflamed patches of skin. It is a common condition that typically begins in infancy or childhood but can persist into adulthood. AD is believed to result from a combination of genetic, immune, and environmental factors, including defects in the skin barrier, immune system dysregulation, and exposure to allergens or irritants. Atopic dermatitis is a widespread chronic inflammatory skin condition, with its prevalence increasing globally, particularly in industrialized nations is boosting the atopic dermatitis(AD) market. For instance, According to the World Allergy Organization (WAO), AD prevalence ranges from 15% to 30% in children and 2% to 10% in adults globally. Moreover, with increasing healthcare expenditure worldwide, patients have greater access to healthcare services and treatments for chronic conditions like atopic dermatitis. For instance, According to a study published in JAMA Dermatology, the annual cost of atopic dermatitis in the United States exceeded $5.3 billion in 2018, with the majority of costs attributed to prescription medications and outpatient visits.

Based on the Drug Class, the market has been categorized into corticosteroids, pde4 inhibitors, calcineurin inhibitors, skin barrier emollients, others. Among them, the corticosteroids segment is expected to grow at a higher CAGR in the market due to several factors, including its well-established efficacy in managing inflammation and itching associated with AD, its widespread availability, and its relatively low cost compared to some newer treatment options. Corticosteroids, whether topical or systemic, have long been a mainstay in the treatment of AD, offering rapid relief of symptoms and helping to control flare-ups. As a result, they remain a popular choice among healthcare providers and patients for the management of mild to moderate AD and as adjunctive therapy in more severe cases.

Based on the end-user, the market has been categorized into hospital pharmacies, retail pharmacies, online pharmacies. Among them, the hospital pharmacies category is to witness higher adoption of atopic dermatitis during the forecast period. The hospital pharmacy segment is experiencing growth in the atopic dermatitis (AD) market due to several factors, including the increasing prevalence of AD, the emergence of new treatment options, and the rising demand for specialized care in hospital settings. Hospitals play a crucial role in the management of AD, particularly in cases of severe disease requiring intensive therapy, multidisciplinary care, or access to advanced treatment modalities. Pharmaceutical companies continue to develop and introduce new treatment options for AD, including biologics, small molecule inhibitors, and novel topical formulations. Moreover, hospital pharmacies may offer specialized compounding services to tailor medications to the specific needs of AD patients.

For a better understanding of the market adoption of the Atopic Dermatitis industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America atopic dermatitis market is expected to continue to grow in the coming years, driven by the increasing prevalence of atopic eczema and growing awareness of atopic dermatitis among the general population, change in lifestyle. For instance, in 2020, according to national eczema.org, 31.6 million people (10.1%) in the U.S. have some form of eczema, and prevalence peaks during early childhood. It is estimated that 1 in 10 individuals will develop eczema during their lifetime, with prevalence peaking in early childhood.

Some of the major players operating in the market include Pfizer Inc., Abbvie Inc., Bristol Myers Squibb, Regeneron Pharmaceuticals, Inc., Evelo Biosciences, Inc., Sanofi, Novartis AG, GALDERMA LABORATORIES, L.P., Eli Lilly and Company (Dermira), Otsuka Pharmaceutical Co., Ltd.

1. MARKET INTRODUCTION

1.1.Market Definitions
1.2.Main Objective
1.3.Stakeholders
1.4.Limitation

2. RESEARCH METHODOLOGY OR ASSUMPTION

2.1.Research Process of the Atopic Dermatitis Market
2.2.Research Methodology of the Atopic Dermatitis Market
2.4.Respondent Profile

3. MARKET SYNOPSIS

4. EXECUTIVE SUMMARY

5. IMPACT OF COVID-19 ON THE ATOPIC DERMATITIS MARKET

6. GLOBAL ATOPIC DERMATITIS MARKET REVENUE, 2020-2030F

7. MARKET INSIGHTS BY DRUG CLASS

7.1.Corticosteroids
7.2.PDE4 Inhibitors
7.3.Calcineurin Inhibitors
7.4.Skin Barrier Emollients
7.5.Others

8. MARKET INSIGHTS BY END USER

8.1.Hospital Pharmacies
8.2.Retail Pharmacies
8.3.Online Pharmacies

9. MARKET INSIGHTS BY REGION

9.1NORTH AMERICA ATOPIC DERMATITIS MARKET
- 9.1.1.U.S.
- 9.1.2.Canada
- 9.1.3.Rest of North America
9.2EUROPE ATOPIC DERMATITIS MARKET
- 9.2.1.Germany
- 9.2.2.U.K.
- 9.2.3.France
- 9.2.4.Italy
- 9.2.5.Spain
- 9.2.6.Rest of Europe
9.3ASIA PACIFIC ATOPIC DERMATITIS MARKET
- 9.3.1.China
- 9.3.2.Japan
- 9.3.3.India
- 9.3.4.Rest of Asia-Pacific
9.4REST OF THE WORLD ATOPIC DERMATITIS MARKET